229 related articles for article (PubMed ID: 30992230)
21. ADAM17, shedding, TACE as therapeutic targets.
Rose-John S
Pharmacol Res; 2013 May; 71():19-22. PubMed ID: 23415892
[TBL] [Abstract][Full Text] [Related]
22. A Disintegrin and Metalloprotease-17 Regulates Pressure Overload-Induced Myocardial Hypertrophy and Dysfunction Through Proteolytic Processing of Integrin β1.
Fan D; Takawale A; Shen M; Samokhvalov V; Basu R; Patel V; Wang X; Fernandez-Patron C; Seubert JM; Oudit GY; Kassiri Z
Hypertension; 2016 Oct; 68(4):937-48. PubMed ID: 27550917
[TBL] [Abstract][Full Text] [Related]
23. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II.
Lorenzen I; Lokau J; Düsterhöft S; Trad A; Garbers C; Scheller J; Rose-John S; Grötzinger J
FEBS Lett; 2012 Apr; 586(8):1093-100. PubMed ID: 22575642
[TBL] [Abstract][Full Text] [Related]
24. iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling.
Li X; Maretzky T; Weskamp G; Monette S; Qing X; Issuree PD; Crawford HC; McIlwain DR; Mak TW; Salmon JE; Blobel CP
Proc Natl Acad Sci U S A; 2015 May; 112(19):6080-5. PubMed ID: 25918388
[TBL] [Abstract][Full Text] [Related]
25. Functional Characterization of Colon Cancer-Associated Mutations in
Pavlenko E; Cabron AS; Arnold P; Dobert JP; Rose-John S; Zunke F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31060243
[TBL] [Abstract][Full Text] [Related]
26. Identification of Molecular Determinants in iRhoms1 and 2 That Contribute to the Substrate Selectivity of Stimulated ADAM17.
Zhao Y; Dávila EM; Li X; Tang B; Rabinowitsch AI; Perez-Aguilar JM; Blobel CP
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361585
[TBL] [Abstract][Full Text] [Related]
27. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
28. Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate.
Kawahara R; Granato DC; Yokoo S; Domingues RR; Trindade DM; Paes Leme AF
J Proteomics; 2017 Jan; 151():53-65. PubMed ID: 27576135
[TBL] [Abstract][Full Text] [Related]
29. [The two sides of ADAM17 in inflammation: implications in atherosclerosis and obesity].
Peiretti F; Canault M; Morange P; Alessi MC; Nalbone G
Med Sci (Paris); 2009 Jan; 25(1):45-50. PubMed ID: 19154693
[TBL] [Abstract][Full Text] [Related]
30. iRhom2: An Emerging Adaptor Regulating Immunity and Disease.
Al-Salihi MA; Lang PA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911849
[TBL] [Abstract][Full Text] [Related]
31. FRMD8 promotes inflammatory and growth factor signalling by stabilising the iRhom/ADAM17 sheddase complex.
Künzel U; Grieve AG; Meng Y; Sieber B; Cowley SA; Freeman M
Elife; 2018 Jun; 7():. PubMed ID: 29897336
[TBL] [Abstract][Full Text] [Related]
32. ADAM17 at the interface between inflammation and autoimmunity.
Lisi S; D'Amore M; Sisto M
Immunol Lett; 2014 Nov; 162(1 Pt A):159-69. PubMed ID: 25171914
[TBL] [Abstract][Full Text] [Related]
33. Role of ADAM17 in kidney disease.
Palau V; Pascual J; Soler MJ; Riera M
Am J Physiol Renal Physiol; 2019 Aug; 317(2):F333-F342. PubMed ID: 31141400
[TBL] [Abstract][Full Text] [Related]
34. Targeting ADAM17 Sheddase Activity in Cancer.
Rossello A; Nuti E; Ferrini S; Fabbi M
Curr Drug Targets; 2016; 17(16):1908-1927. PubMed ID: 27469341
[TBL] [Abstract][Full Text] [Related]
35. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.
Moss ML; Minond D
Mediators Inflamm; 2017; 2017():9673537. PubMed ID: 29230082
[TBL] [Abstract][Full Text] [Related]
36. Production of porcine TNFα by ADAM17-mediated cleavage negatively regulates porcine reproductive and respiratory syndrome virus infection.
Li R; Guo L; Gu W; Luo X; Zhang J; Xu Y; Tian Z; Feng L; Wang Y
Immunol Res; 2016 Jun; 64(3):711-20. PubMed ID: 26724939
[TBL] [Abstract][Full Text] [Related]
37. The Role of ADAM17 in Inflammation-Related Atherosclerosis.
Tang BY; Ge J; Wu Y; Wen J; Tang XH
J Cardiovasc Transl Res; 2022 Dec; 15(6):1283-1296. PubMed ID: 35648358
[TBL] [Abstract][Full Text] [Related]
38. Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution.
Calligaris M; Cuffaro D; Bonelli S; Spanò DP; Rossello A; Nuti E; Scilabra SD
Molecules; 2021 Feb; 26(4):. PubMed ID: 33579029
[TBL] [Abstract][Full Text] [Related]
39. ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer.
Schumacher N; Rose-John S
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694340
[TBL] [Abstract][Full Text] [Related]
40. Skin Barrier Defects Caused by Keratinocyte-Specific Deletion of ADAM17 or EGFR Are Based on Highly Similar Proteome and Degradome Alterations.
Tholen S; Wolf C; Mayer B; Knopf JD; Löffek S; Qian Y; Kizhakkedathu JN; Biniossek ML; Franzke CW; Schilling O
J Proteome Res; 2016 May; 15(5):1402-17. PubMed ID: 27089454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
